Quick Answer
Coya Therapeutics, Inc. reported Operating Income Loss of -$22.56 million for the year ending 2025.
- Coya Therapeutics, Inc. showed a decrease of -30.8% in Operating Income Loss from 2024 to 2025.
- This data is from Coya Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2021 to 2025), Coya Therapeutics, Inc.'s Operating Income Loss has declined by 363.1%.
- Historical annual values: Fiscal year 2025: -$22.56 million | Fiscal year 2024: -$17.25 million | Fiscal year 2023: -$7.90 million | Fiscal year 2022: -$9.81 million | Fiscal year 2021: -$4.87 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: